Literature DB >> 1580449

Pharmaceutical advertisements in leading medical journals: experts' assessments.

M S Wilkes1, B H Doblin, M F Shapiro.   

Abstract

OBJECTIVE: To assess both the accuracy of scientific data presented in print pharmaceutical advertisements and the compliance of these advertisements with current Food and Drug Administration (FDA) standards.
DESIGN: Cross-sectional survey. MEASUREMENTS: Each full-page pharmaceutical advertisement (n = 109) appearing in 10 leading medical journals, along with all available references cited in the advertisement (82% of the references cited were available) were sent to three reviewers: two physicians in the relevant clinical area who were experienced in peer review and one academic clinical pharmacist. Reviewers, 95% of whom responded, were asked to evaluate the advertisements using criteria based on FDA guidelines, to judge the educational value and overall quality of the advertisements, and to make a recommendation regarding publication.
RESULTS: In 30% of cases, two or more reviewers disagreed with the advertisers' claim that the drug was the "drug of choice." Reviewers felt that information on efficacy was balanced with that on side effects and contraindications in 49% of advertisements but was not balanced in 40%. Reviewers agreed with advertisements' claims that the drug was safe in 86% of the cases but judged that headlines in 32% of the advertisements containing headlines misled the reader about efficacy. In 44% of cases, reviewers felt that the advertisement would lead to improper prescribing if a physician had no other information about the drug other than that contained in the advertisement. Fifty-seven percent of advertisements were judged by two or more reviewers to have little or no educational value. Overall, reviewers would not have recommended publication of 28% of the advertisements and would have required major revisions in 34% before publication.
CONCLUSION: In the opinion of the reviewers, many advertisements contained deficiencies in areas in which the FDA has established explicit standards of quality. New strategies are needed to ensure that advertisements comply with standards intended to promote proper use of the products and to protect the consumer.

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Substances:

Year:  1992        PMID: 1580449     DOI: 10.7326/0003-4819-116-11-912

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  49 in total

1.  Pharmaceutical advertising revenue and physician organizations: how much is too much?

Authors:  P A Glassman; J Hunter-Hayes; T Nakamura
Journal:  West J Med       Date:  1999-10

2.  Guidelines for advertising on health web sites: who's guarding the Koop.

Authors:  M K Cho
Journal:  West J Med       Date:  2000-04

3.  Selling drugs to the public--should the UK follow the example of the US?

Authors:  John Frey
Journal:  Br J Gen Pract       Date:  2002-02       Impact factor: 5.386

4.  Selling drugs to doctors--it's marketing, not education.

Authors:  Richelle Cooper; Jerome Hoffman
Journal:  Br J Gen Pract       Date:  2002-02       Impact factor: 5.386

5.  "Educational" advertisements--I haven't seen one yet!

Authors:  L A Bero
Journal:  West J Med       Date:  2001-06

6.  Do drug advertisements in Russian medical journals provide essential information for safe prescribing?

Authors:  V Vlassov; P Mansfield; J Lexchin; A Vlassova
Journal:  West J Med       Date:  2001-06

7.  You can't leap a chasm in two jumps: The Institute of Medicine health care quality report.

Authors:  G D Schiff; Q D Young
Journal:  Public Health Rep       Date:  2001 Sep-Oct       Impact factor: 2.792

8.  Direct to consumer advertising of prescription drugs. An idea whose time should not come.

Authors:  J R Hoffman; M Wilkes
Journal:  BMJ       Date:  1999-05-15

9.  The quantity and quality of scientific graphs in pharmaceutical advertisements.

Authors:  Richelle J Cooper; David L Schriger; Roger C Wallace; Vladislav J Mikulich; Michael S Wilkes
Journal:  J Gen Intern Med       Date:  2003-04       Impact factor: 5.128

10.  New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?

Authors:  Joel Lexchin
Journal:  Can Fam Physician       Date:  2002-09       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.